Monarch Therapeutics, SNAP Biosciences enter licensing agreement

SNAP Biosciences and Monarch Therapeutics announced a licensing agreement to enable the development and commercialization of SNAP Biosciences’ proprietary Snap-Car NK cell therapy platform in oncology using Monarch’s small molecule adaptor technology. This agreement grants SNAP Biosciences access to Monarch’s novel small-molecule adaptor-based technology platform, significantly broadening the functionality of the Snap-Car universal CAR-based receptor platform. Monarch’s ground-breaking small molecule approach, invented by Monarch’s scientific co-founders Drs. Jason Lohmueller and Alexander Deiters, enables SNAP-CAR cells to be directed by small molecule-based adaptors, enhancing the system’s precision, flexibility, and modular potential across diverse therapeutic areas. Under the terms of the agreement, Monarch will receive an upfront licensing payment and is eligible for future development milestone payments, as well as royalties on net sales.